Zogenix Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
33,012.00
40,531.00
27,182.00
28,850.00
9,821.00
155
Cost of Goods Sold (COGS) incl. D&A
21,241.00
31,877.00
22,356.00
22,173.00
10,729.00
155
Gross Income
11,771.00
8,654.00
4,826.00
6,677.00
908.00
155
SG&A Expense
64,087.00
107,535.00
54,552.00
69,131.00
93,334.00
139,720
EBIT
52,316.00
98,881.00
-
62,454.00
94,242.00
139,875
Unusual Expense
22,044.00
22,926.00
897.00
4,844.00
30,273.00
1,131
Non Operating Income/Expense
96.00
87,696.00
5,817.00
46.00
47.00
10,126
Interest Expense
6,610.00
3,090.00
3,060.00
2,825.00
2,644.00
6
Pretax Income
80,856.00
8,671.00
57,605.00
69,634.00
126,022.00
123,716
Income Tax
-
84.00
15,901.00
948.00
-
-
Consolidated Net Income
80,856.00
8,587.00
41,704.00
68,686.00
126,022.00
123,716
Net Income
80,856.00
8,587.00
41,704.00
68,686.00
126,022.00
123,716
Net Income After Extraordinaries
80,856.00
8,587.00
109,552.00
67,665.00
125,227.00
123,518
Net Income Available to Common
80,856.00
8,587.00
26,144.00
69,707.00
126,817.00
123,914
EPS (Basic)
5.92
0.48
1.22
2.81
4.65
3.27
Basic Shares Outstanding
13,571.00
17,825.90
21,449.00
24,785.00
27,301.00
37,884
EPS (Diluted)
5.96
0.47
1.22
2.81
4.65
3.27
Diluted Shares Outstanding
13,571.00
18,130.80
21,449.00
24,785.00
27,301.00
37,884
EBITDA
50,510.00
97,256.00
48,105.00
61,052.00
93,817.00
139,720
Non-Operating Interest Income
18.00
20.00
101.00
443.00
1,090.00
7,170

About Zogenix

View Profile
Address
5959 Horton Street
Emeryville California 94608
United States
Employees -
Website http://www.zogenix.com
Updated 07/08/2019
Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.